Sheila M Alessi1, Nancy P Barnett2, Nancy M Petry3. 1. University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-3944, United States. Electronic address: salessi@uchc.edu. 2. Center for Alcohol and Addiction Studies, School of Public Health, Brown University, Box G-S121-5, Providence, RI 02912, United States. Electronic address: Nancy_Barnett@brown.edu. 3. University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-3944, United States.
Abstract
BACKGROUND: Transdermal alcohol sensing technology allows for objective continuous monitoring of alcohol use. The purpose of this study was to characterize alcohol consumption measured with this technology among alcohol use disorder treatment outpatients in two clinical trials. METHODS: Participants were community-based alcohol treatment outpatients in usual care (N = 63) during the first three years of studies that monitored drinking with the secure continuous remote alcohol monitor (SCRAMx®) ankle bracelet. Research visits for uploading SCRAMx data occurred every other week in Study 1 (n = 43) and once weekly in Study 2 (n = 20), for 3 months. Staff used timeline follow-back procedures to collect self-reports of drinking frequency and magnitude at each research visit. RESULTS: In the 90 days before intake, 85.7% (n = 54) of participants reported consuming alcohol, and consumption occurred on a median (interquartile range) 35.7% (29.0%) of days. During the treatment period, per SCRAMx versus self-report, the percentage who drank was 92.1% (n = 58) versus 46.6% (n = 30), p = .03, and consumption occurred on 16.5% (36.5%) versus 0.0% (21.4%) of days, respectively, p < .001. Median longest duration of abstinence was 26.0 (25.0) versus 39.0 (58.0) days, respectively, p < .001. Breath alcohol concentration, estimated from SCRAMx data, ranged from 0.02 to 0.91 g/dL. CONCLUSIONS: This is the first study to quantify alcohol consumption among alcohol treatment outpatients using transdermal sensor technology. Results indicate that most patients drank while in outpatient care. Issues to consider for future applications of this technology and implications for alcohol treatment are discussed.
BACKGROUND: Transdermal alcohol sensing technology allows for objective continuous monitoring of alcohol use. The purpose of this study was to characterize alcohol consumption measured with this technology among alcohol use disorder treatment outpatients in two clinical trials. METHODS:Participants were community-based alcohol treatment outpatients in usual care (N = 63) during the first three years of studies that monitored drinking with the secure continuous remote alcohol monitor (SCRAMx®) ankle bracelet. Research visits for uploading SCRAMx data occurred every other week in Study 1 (n = 43) and once weekly in Study 2 (n = 20), for 3 months. Staff used timeline follow-back procedures to collect self-reports of drinking frequency and magnitude at each research visit. RESULTS: In the 90 days before intake, 85.7% (n = 54) of participants reported consuming alcohol, and consumption occurred on a median (interquartile range) 35.7% (29.0%) of days. During the treatment period, per SCRAMx versus self-report, the percentage who drank was 92.1% (n = 58) versus 46.6% (n = 30), p = .03, and consumption occurred on 16.5% (36.5%) versus 0.0% (21.4%) of days, respectively, p < .001. Median longest duration of abstinence was 26.0 (25.0) versus 39.0 (58.0) days, respectively, p < .001. Breath alcohol concentration, estimated from SCRAMx data, ranged from 0.02 to 0.91 g/dL. CONCLUSIONS: This is the first study to quantify alcohol consumption among alcohol treatment outpatients using transdermal sensor technology. Results indicate that most patients drank while in outpatient care. Issues to consider for future applications of this technology and implications for alcohol treatment are discussed.
Authors: Nancy M Petry; Ken B Kolodner; Rui Li; Jessica M Peirce; John M Roll; Maxine L Stitzer; John A Hamilton Journal: Drug Alcohol Depend Date: 2006-01-10 Impact factor: 4.492
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Nancy P Barnett; Jennifer Tidey; James G Murphy; Robert Swift; Suzanne M Colby Journal: Drug Alcohol Depend Date: 2011-06-12 Impact factor: 4.492
Authors: John D Roache; Tara E Karns; Nathalie Hill-Kapturczak; Jillian Mullen; Yuanyuan Liang; Richard J Lamb; Donald M Dougherty Journal: Alcohol Clin Exp Res Date: 2015-05-18 Impact factor: 3.455
Authors: Matthew Brensilver; Keith G Heinzerling; Aimee-Noelle Swanson; Steven J Shoptaw Journal: Exp Clin Psychopharmacol Date: 2012-08-06 Impact factor: 3.157
Authors: Garrett I Ash; Ralitza Gueorguieva; Nancy P Barnett; Wuyi Wang; David S Robledo; Kelly S DeMartini; Brian Pittman; Nancy S Redeker; Stephanie S O'Malley; Lisa M Fucito Journal: Alcohol Clin Exp Res Date: 2022-05-14 Impact factor: 3.928
Authors: Baichen Li; R Scott Downen; Quan Dong; Nam Tran; Maxine LeSaux; Andrew C Meltzer; Zhenyu Li Journal: IEEE Sens J Date: 2020-10-12 Impact factor: 3.301
Authors: Yan Wang; Daniel J Fridberg; Destin D Shortell; Robert F Leeman; Nancy P Barnett; Robert L Cook; Eric C Porges Journal: Alcohol Date: 2021-02-18 Impact factor: 2.558
Authors: Eun-Young Mun; Xiaoyin Li; Michael S Businelle; Emily T Hébert; Zhengqi Tan; Nancy P Barnett; Scott T Walters Journal: Alcohol Clin Exp Res Date: 2021-03-03 Impact factor: 3.455
Authors: Andreas Zetterström; Markku D Hämäläinen; Maria Winkvist; Marcus Söderquist; Patrik Öhagen; Karl Andersson; Fred Nyberg Journal: Front Digit Health Date: 2021-12-07